Why the study?
The initial purpose was to determine whether PAI-1 deletion influenced ATAA development, and subsequently to define early pathological events preceding cardiac fibrosis in PAI-1 deficiency and the protective structural domain.
PAI-1 deficiency promotes early cardiac hemorrhage and subsequent fibrosis under hemodynamic stress, suggesting a protective role for PAI-1's protease-inhibitory function against hypertensive cardiac injury.
Answers are grounded in this paper and cite their sources.
PAI-1 deletion effects in AngII models warrant caution in preclinical targeting; leaves open human ATAA and fibrosis mechanisms.
Aims Plasminogen activator inhibitor-1 (PAI-1) regulates plasmin-mediated proteolysis, thereby influencing vascular stability and tissue remodeling. Angiotensin II (AngII) induces an increase in PAI-1 during the development of ascending thoracic aortic aneurysm (ATAA). The initial purpose of this study was to determine whether deletion of PAI-1 influenced development of ATAA. Subsequently, this study aimed to define the early pathological events preceding cardiac fibrosis in PAI-1 deficiency and the structural domain responsible for its protective effect. Methods and results AngII was infused for 4 weeks in whole-body PAI-1 deficient (PAI-1−/−) mice and their wild-type littermates (PAI-1+/+) to examine the role of PAI-1 in ATAA. PAI-1 deficiency did not alter AngII-induced aortopathy but revealed a striking cardiac phenotype characterized by replacement fibrosis predominantly within the epicardium and posterior septum. Ferric iron, indicative of prior hemorrhage, was coincident with fibrosis. Similar phenotypes were observed in PAI-1−/− mice infused with norepinephrine for 4 weeks. To define the pathological events preceding cardiac fibrosis, either AngII or norepinephrine was infused for 1 week in PAI-1+/+ or −/− mice. Both infusions induced extensive epicardial hemorrhage and posterior septal fibrosis in PAI-1−/− mice. To explore the initiation of cardiac pathology, AngII was infused for approximately 1 day. PAI-1−/− mice developed diffuse hemorrhage and cardiomyocyte injury localized to the posterior septum, pathologic changes that preceded overt fibrosis. Finally, to determine the protective domain of PAI-1, saline or AngII was administered to mice harboring loss-of-function point mutations in the protease inhibitory (PAI-1 Ala/Ala ) or somatomedin B-binding domains (PAI-1 AK/AK ). Compared to saline infusion, 1 week of AngII induced hemorrhage and heterogeneous fibrosis in PAI-1 Ala/Ala , but not PAI-1 AK/AK mice. Conclusions These findings support that, under hemodynamic stress, PAI-1 deficiency promotes early cardiac hemorrhage and cardiomyocyte injury that lead to fibrosis. Mutational studies implicate dysregulated plasmin generation as an initiator of cardiac injury and fibrosis. TRANSLATIONAL PERSPECTIVE Cardiac fibrosis has been reported in a human population with PAI-1 deficiency and currently lacks targeted therapy. Our findings demonstrate that in animal models, PAI-1 deficiency confers susceptibility to cardiac injury in response to hemodynamic stress, which may accelerate fibrotic remodeling. Mutational disruption of the protease-inhibitory domain of PAI-1 induced similar pathology, supporting a protective role for this function. These observations suggest that interventions aimed at controlling hypertension, promoting endothelial integrity, or regulating plasmin activation could reduce fibrotic remodeling in this population.
No takes yet. Share an insight, caveat, or question.
Pettey et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: